• Citer

A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis.

par Rice, Todd W;Wheeler, Arthur;Bernard, Gordon;Vincent, Jean Louis ;Angus, Derek;Aikawa, Naoki;Demeyer, Ignace;Sainati, Stephen;Amlot, Nicholas;Cao, Charlie;Ii, Masayuki;Matsuda, Hideyasu;Mouri, Kouji;Cohen, Jonathan
Référence Critical care medicine, 38, 8, page (1685-1694)
Publication Publié, 2010-08

Article révisé par les pairs

• Détails
• Contenu

Titre:	A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis.
Auteur:	Rice, Todd W; Wheeler, Arthur; Bernard, Gordon; Vincent, Jean Louis; Angus, Derek; Aikawa, Naoki; Demeyer, Ignace; Sainati, Stephen; Amlot, Nicholas; Cao, Charlie; Ii, Masayuki; Matsuda, Hideyasu; Mouri, Kouji; Cohen, Jonathan
Informations sur la publication:	Critical care medicine, 38, 8, page (1685-1694)
Statut de publication:	Publié, 2010-08
Sujet CREF:	Sciences bio-médicales et agricoles
Mots-clés:	cytokines
	interleukin-6
	mortality
	severe sepsis
	TAK-242
	Toll-like receptor-4
	Toll-like receptors
MeSH keywords:	Adult
	Aged
	Cytokines -- drug effects -- metabolism
	Dose-Response Relationship, Drug
	Double-Blind Method
	Drug Administration Schedule
	Female
	Follow-Up Studies
	Hospital Mortality -- trends
	Humans
	Infusions, Intravenous
	Male
	Middle Aged
	Multiple Organ Failure -- prevention & control
	Probability
	Pulse Therapy, Drug
	Reference Values
	Risk Assessment
	Sepsis -- diagnosis -- drug therapy -- mortality
	Sulfonamides -- administration & dosage -- adverse effects
	Survival Analysis
	Treatment Outcome
Note générale:	Comparative Study
	Journal Article
	Multicenter Study
	Randomized Controlled Trial
	Research Support, Non-U.S. Gov't
	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0090-3493
	info:doi/10.1097/CCM.0b013e3181e7c5c9
	info:pii/S0090349310604130
	info:scp/77954953617
	info:pmid/20562702